WO2009030084A1 - NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ - Google Patents

NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ Download PDF

Info

Publication number
WO2009030084A1
WO2009030084A1 PCT/CN2007/070623 CN2007070623W WO2009030084A1 WO 2009030084 A1 WO2009030084 A1 WO 2009030084A1 CN 2007070623 W CN2007070623 W CN 2007070623W WO 2009030084 A1 WO2009030084 A1 WO 2009030084A1
Authority
WO
WIPO (PCT)
Prior art keywords
rabj
polypeptide
tumor
protein
cells
Prior art date
Application number
PCT/CN2007/070623
Other languages
English (en)
Chinese (zh)
Inventor
Taoyong Chen
Nan Li
Tao Wan
Xuetao Cao
Original Assignee
Second Military Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Military Medical University filed Critical Second Military Medical University
Priority to PCT/CN2007/070623 priority Critical patent/WO2009030084A1/fr
Publication of WO2009030084A1 publication Critical patent/WO2009030084A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention is in the field of biotechnology and medicine, and in particular, the present invention relates to human oncogene-like small G protein RabJ and its coding sequence.
  • the polypeptide of the present invention is a novel molecule having GTPase activity, which is involved in the regulation of cell proliferation and cell differentiation, and has an oncogene-like effect. Background technique
  • Small G proteins refer to single subunit G proteins with a molecular weight of about 20-30 kDa.
  • GTP guanosine triphosphate
  • GDP guanosine diphosphate
  • Phosphoric acid becomes GDP (ie GTPase activity;).
  • Ras Ras, Rab, Rho, Arf, Sari and Ran.
  • Ras and Rho families are extremely important small G proteins because they are involved in the regulation of signaling mechanisms, so that cells can respond correctly to external stimuli and play an important role in basic life activities such as cell survival and apoptosis.
  • Members of the Ras family include Ras, Ral, and Rap, and the most widely known of them are the Ras subfamily, including Ha-Ras, Ki-Ras, and N-Ras. Both knockout mouse models and defective cell models have demonstrated that Ras family molecules play an important role in embryogenesis and ontogeny.
  • Rho family mainly include Rho, Rac, Cdc42, etc., by regulating the functions and activities of Rho-associated kinase (ROK), myosin binding subunit (MBS) phospholipase and other target proteins. Regulate cellular activities such as cytoskeleton, cell proliferation, and stress response.
  • ROK Rho-associated kinase
  • MMS myosin binding subunit
  • Ras and tumorigenesis and their role in the regulation of cell proliferation have attracted attention.
  • mutations in the H-Ras, K-Ras or N-Ras genes and Ras mutations are the most likely in tumor-mutated genes.
  • Molecules associated with the regulation of Ras protein activity are also involved in tumorigenesis.
  • Molecules of the Rho family also regulate the formation of intracellular actin-stressing fibers, cell membrane processes, and depressions by regulating the cellular actin system.
  • NIH3T3 a mutant protein molecule that regulates the activity of the Rho family can cause cell transformation.
  • Rho family oncogene-like molecules that regulate the GTP/GDP binding activity and GTPase activity of the Rho family include Dbl, Vav, Lbc, Tiaml, Tim, Ost, Ect2, Lsc, and FGD1, which can cause abnormalities in the function of the cell actin system, causing cells. Changes in migration infiltration capacity.
  • Rab Ras-like protein in rat brain
  • the basic biochemical feature is that it can bind GTP/GDP and hydrolyze GTP. So far, the family has grown to more than 100 members, including in many species including nematodes, yeast, fruit fly, zebrafish, mice, rats, humans, etc., mainly involved in intracellular proteins.
  • the transport process regulates the fusion of membranous organelles and the process of budding, anchoring and fusion of microvesicles, regulating cell activities such as protein synthesis, endocytosis, degradation and secretion.
  • Different Rab proteins often have different subcellular localizations and thus can locally regulate the fine protein transport process.
  • Rabla, Rablb, Rab2 localize to the endoplasmic reticulum and Golgi and mediate the transport of substances between the two; Rab6, Rab8, Rabl2 are associated with the Golgi apparatus and mediate the transport of substances between different Golgi sites.
  • Another object of the invention is to provide the use of the polypeptide and the coding sequence.
  • an antagonist of a human RabJ polypeptide for use in the preparation of a composition for inhibiting tumor formation or tumor growth.
  • the antagonist is an antibody, an antisense nucleotide or an interfering RNA.
  • the RabJ polypeptide is selected from the group consisting of:
  • amino acid sequence of SEQ ID NO: 2 is formed by substitution, deletion or addition of one or more amino acid residues, and has the function of promoting the formation of clones of Hela cells or MCF-7 cells on soft agar in vitro.
  • a derived polypeptide is formed by substitution, deletion or addition of one or more amino acid residues, and has the function of promoting the formation of clones of Hela cells or MCF-7 cells on soft agar in vitro.
  • the composition is a pharmaceutical composition.
  • the antibody is a monoclonal antibody or a polyclonal antibody.
  • sequence of the interfering RNA is SEQ ID NO: 9.
  • the tumor is selected from the group consisting of lung cancer, breast cancer, liver cancer, or gastric cancer.
  • the composition is also useful for reducing tumorigenicity of tumor cells in vivo.
  • a human RabJ polypeptide or a coding sequence thereof for screening for a therapeutic agent which inhibits tumor formation or tumor growth by interaction with a human RabJ polypeptide or a coding sequence thereof .
  • a method of screening for a therapeutic agent that inhibits tumor cell growth comprising the steps of:
  • control group is a culture system of a tumor cell expressing a RabJ polypeptide or a culture system of a tumor cell to which a RabJ polypeptide is added
  • test group is added with a test substance a culture system of a tumor cell expressing a RabJ polypeptide, or a culture system of a tumor cell to which a test substance and a RabJ polypeptide are added;
  • the growth rate of the tumor cells in the test group was smaller than that of the control group, indicating that the test substance is a potential therapeutic agent for inhibiting the growth of tumor cells.
  • the test substance is an interfering RNA.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a human
  • the antagonist is an interfering RNA having the sequence SEQ ID NO: 9.
  • SEQ ID NO: 9 the sequence SEQ ID NO: 9.
  • Figure 1 is a Northern blot analysis of human RabJ protein human RabJ expression in normal human tissues of the present invention.
  • the knot prompts that the RabJ protein is selectively expressed in testicular tissue.
  • Fig. 2 is a diagram showing the expression and purification of the human RabJ protein of the present invention and the biochemical characteristics of the RabJ protein. The results showed that the RabJ protein has binding GTP/GDP activity and GTPase activity.
  • Figure 3 is a Western blot analysis of RabJ protein expressed by NIH3T3 cells transfected with eukaryotic recombinant expression vector of human RabJ of the present invention.
  • Figure 4 is an analysis of RNA interference of human RabJ protein expression in HeLa and B MCF-7 cells.
  • Figure 5 is a proliferative effect of human RabJ protein overexpression on NIH3T3 cells of the present invention. The results suggest that overexpression of RabJ protein significantly promoted the proliferation of NIH3T3 cells.
  • Fig. 6 is a graph showing the inhibitory effect on the proliferation of HeLa and MCF-7 cells after down-regulation of human RabJ protein expression of the present invention. The results suggest that down-regulation of RabJ protein expression can inhibit the proliferation of HeLa and MCF-7 cells.
  • Figure 7 is a graph showing the in vitro transformation of NIH3T3 cells induced by high expression of the human RabJ protein of the present invention. Among them, the results are expressed as the number of cells forming the focus or the number of clones/plating ⁇ 100%.
  • Figure 8 is a graph showing that the down-regulation of human RabJ protein expression of the present invention inhibits the clonality of HeLa and MCF-7 cells.
  • Figure 10 is a graph showing that down-regulation of human RabJ protein inhibits in vivo tumorigenicity (A) and tumor growth rate (B) of HeLa cells. detailed description
  • RabJ The coding sequence of RabJ is isolated from a human dendritic cell cDNA library, and its sequence is shown in SEQ ID NO: 1, which comprises a polynucleotide sequence of 1787 bases in length and an open reading frame at 25- 846 digits, the full length of the code is 273 Amino acid human RabJ protein (SEQ ID NO: 2).
  • SEQ ID NO: 1 comprises a polynucleotide sequence of 1787 bases in length and an open reading frame at 25- 846 digits, the full length of the code is 273 Amino acid human RabJ protein (SEQ ID NO: 2).
  • SEQ ID NO: 2 Amino acid human RabJ protein
  • NIH3T3 Normal fibroblasts NIH3T3 are transformed after high expression of RabJ, which is expressed as colonies on semi-solid agar plates, and RabJ-transformed NIH3T3 cells can be used in nude mice.
  • RabJ can promote cell proliferation. Blocking the expression of RabJ using RNA interference technology can inhibit the proliferation of tumor cells, resulting in decreased tumorigenicity and decreased tumor growth rate in vivo. Therefore, RabJ can be used as an effective target for tumor therapy.
  • RabJ protein refers to a protein having the testis function-related protein RabJ amino acid sequence (SEQ ID NO: 2 or 4) or Peptide. They include the testicular function-related protein RabJ with or without the initial methionine.
  • hRabJ refers to a human RabJ molecule
  • mRabJ refers to a mouse-derived homolog of hRabJ.
  • RabJ may be involved in the thermal protection of testes and other protection against adverse factors; it may be used for the diagnosis and treatment of reproductive dysfunction and testicular diseases such as tumors, trauma, dysplasia, etc.; The diagnosis and treatment of abnormal diseases is also extremely meaningful.
  • isolated means that the substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment;).
  • the polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotide or polypeptide is separated and purified, such as from other substances existing in the natural state. .
  • isolated RabJ protein or polypeptide means that the RabJ polypeptide is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. Those skilled in the art will be able to purify the RabJ protein using standard protein purification techniques. A substantially pure polypeptide produces a single major band on a non-reducing polyacrylamide gel. The purity of the RabJ polypeptide can be analyzed by amino acid sequence.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, preferably a recombinant polypeptide.
  • the polypeptide of the present invention may be a naturally purified product, or a chemically synthesized product, or produced by recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plant, insect, and mammalian cells;
  • the polypeptide of the invention may be glycosylated, or may be non-glycosylated, depending on the host used in the recombinant production protocol.
  • Polypeptides of the invention may also or may not include an initial methionine residue.
  • the invention also includes fragments, derivatives and analogs of RabJ polypeptides.
  • fragment refers to a polypeptide that substantially retains the same biological function or activity of a native RabJ polypeptide of the invention.
  • the polypeptide fragment, derivative or analog of the present invention may be a polypeptide in which ⁇ has one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues;), and such substituted amino acid residues may Is not also encoded by the genetic code, or (H) a polypeptide having a substituent group in one or more amino acid residues, or o a mature polypeptide and another compound (such as a compound that extends the half-life of the polypeptide, such as polyethylene-2) An alcohol; a polypeptide formed by fusion of the polypeptide, or (IV) an additional amino acid sequence fused to the polypeptide sequence (such as a leader or secretion sequence or a sequence or proprotein sequence used to purify the polypeptide, or with an antigen IgG) Fragment Formation of the fusion protein ;).
  • ⁇ has one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues;), and such substituted amino acid residues may Is not also
  • RabJ polypeptide means a polypeptide having the sequence of SEQ ID NO. 2 or 4 having RabJ polypeptide activity.
  • the term also encompasses variant forms of the sequence of SEQ ID NO. 2 or 4 that have the same function as the RabJ polypeptide. These variants include (but are not limited to;): several (usually 1-50, preferably 1-30, more preferably 1-20, optimally 1-10;) amino acid deletions Insertion and/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and/or N-terminus.
  • the function of the protein is usually not altered.
  • the addition of one or more amino acids at the C-terminus and/or N-terminus will generally not alter the function of the protein.
  • the term also encompasses active fragments and active derivatives of RabJ polypeptides.
  • Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that hybridize to human RabJ DNA under high or low stringency conditions And a polypeptide or protein obtained using an antiserum against the RabJ polypeptide.
  • the invention also provides other polypeptides, such as fusion proteins comprising a RabJ polypeptide or a fragment thereof.
  • the present invention also encompasses soluble fragments of the RabJ polypeptide.
  • the fragment has at least about 10 contiguous amino acids of the RabJ polypeptide sequence, typically at least about 30 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100.
  • a contiguous amino acid typically at least about 10 contiguous amino acids of the RabJ polypeptide sequence, typically at least about 30 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100.
  • the invention also provides analogs of RabJ polypeptides or polypeptides.
  • the difference between these analogs and the native RabJ polypeptide may be a difference in amino acid sequence, a difference in the modification form which does not affect the sequence, or a combination thereof.
  • RabJ polypeptide conservative variant polypeptide means up to 10, preferably up to 8, more preferably up to 5, optimally compared to the amino acid sequence of SEQ ID NO: 2 or 4. Up to 3 amino acids are replaced by amino acids of similar or similar nature to form a polypeptide.
  • the polynucleotide of the present invention may be in the form of DNA or RNA.
  • DNA forms include cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • the DNA can be either a coding strand or a non-coding strand.
  • the coding region sequence encoding the mature polypeptide may be identical to the coding region sequence shown in SEQ ID NO: l or a degenerate variant.
  • a "degenerate variant" in the present invention refers to a nucleic acid sequence which encodes a protein having SEQ ID NO: 2 but differs from the coding region sequence shown in SEQ ID NO: 1.
  • Polynucleotides encoding mature polypeptides of RabJ include: coding sequences encoding only mature polypeptides; coding sequences for mature polypeptides and various additional coding sequences; coding sequences for mature polypeptides (and optionally additional coding sequences;) and non-coding sequences .
  • polynucleotide encoding a polypeptide may be a polynucleotide comprising the polypeptide, or a polynucleotide further comprising an additional coding and/or non-coding sequence.
  • the present invention also relates to a variant of the above polynucleotide which encodes the same amino acid sequence as the present invention. Fragments, analogs and derivatives of peptides or polypeptides. Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants. As is known in the art, an allelic variant is an alternative form of a polynucleotide which may be a substitution, deletion or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide encoded thereby. .
  • the invention also relates to hybridization to the sequences described above and having at least 50% between the two sequences, preferably at least
  • hybridizable polynucleotide has the same biological function and activity as the mature polypeptide of SEQ ID NO: 2.
  • the full-length human RabJ nucleotide sequence of the present invention or a fragment thereof can be usually obtained by a PCR amplification method, a recombinant method or a synthetic method.
  • primers can be designed in accordance with the disclosed nucleotide sequences, particularly open reading frame sequences, and can be prepared using commercially available cDNA libraries or conventional methods known to those skilled in the art.
  • the library is used as a template to amplify the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then the amplified fragments are spliced together in the correct order.
  • the recombination method can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it to a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.
  • synthetic sequences can be used to synthesize related sequences, especially when the fragment length is short.
  • a long sequence of fragments can be obtained by first synthesizing a plurality of small fragments and then connecting them.
  • the invention also relates to vectors comprising the polynucleotides of the invention, and host cells genetically engineered using the vectors or RabJ protein coding sequences of the invention, and methods of producing the polypeptides of the invention by recombinant techniques.
  • polynucleotide sequences of the present invention can be utilized to express or produce recombinant RabJ polypeptides by conventional recombinant DNA techniques. Generally there are the following steps:
  • the invention also relates to antagonists of RabJ polypeptides.
  • an antagonist of a RabJ polypeptide refers to a substance that is capable of combating, or reducing, the activity or expression of a RabJ polypeptide.
  • Common antagonists are antibodies, antisense nucleotides, and interfering RNA (RNAi).
  • RNAi interfering RNA
  • An antagonist or the like of the protein of the present invention when administered therapeutically (administered;), can be used for inhibiting tumor formation or for inhibiting growth of tumor cells.
  • these materials can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium wherein the pH is usually from about 5 to about 8, preferably from about 6 to about 8, although the pH may be The nature of the formulation and the condition to be treated vary.
  • the formulated pharmaceutical compositions can be administered by conventional routes including, but not limited to, intramuscular, intraperitoneal, intravenous, subcutaneous, intradermal, or topical administration.
  • an antagonist of RabJ polypeptide can be directly used for the treatment of diseases, for example, for the treatment of diseases such as tumors (such as lung cancer, breast cancer).
  • diseases such as tumors (such as lung cancer, breast cancer).
  • other therapeutic agents can also be used at the same time.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a safe and effective amount of a RabJ polypeptide antagonist of the invention and a pharmaceutically acceptable carrier or excipient.
  • Such carriers include, but are not limited to;: saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof.
  • the pharmaceutical preparation should be matched to the mode of administration.
  • the pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods.
  • Pharmaceutical compositions such as injections, solutions, tablets and capsules are preferably prepared under sterile conditions.
  • the active ingredient is administered in a therapeutically effective amount, for example, from about 1 microgram per kilogram of body weight to about 5 milligrams per kilogram of body weight per day.
  • a safe and effective amount of a RabJ protein antagonist is administered to the mammal, wherein the safe and effective amount is usually at least about 1 microgram per kilogram of body weight, and in most cases no more than about 8 milligrams per kilogram of body weight, Preferably, the dosage is from about 10 micrograms per kilogram of body weight to about 1 milligram per kilogram of body weight.
  • specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
  • the corresponding antagonist can be used to inhibit tumor formation and reduce tumorigenicity for cancer treatment;
  • RabJ can be used as an effective tumor therapeutic target for screening therapeutic agents for treating tumors by interacting with RabJ.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are only intended to illustrate the invention and not to limit the scope of the invention.
  • the experimental methods in the following examples which do not specify the specific conditions are usually carried out according to the conditions described in conventional conditions such as Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer. The suggested conditions.
  • Example 1 Cloning of human RabJ cDNA
  • RNA from human dendritic cells was extracted with Tnzol reagent (Invitrogen). Then, poly(A) mRNA is isolated from total RNA. After the reverse transcription of poly(A) mRNA to form cDNA, SuperScnptll cloning reagent was used. The cassette (Invitrogen) was inserted into the cloning site of the vector, and the DH5oc bacteria were transformed to form a cDNA plasmid library. The sequence of the 5' end of the randomly selected clone was determined by the dideoxy method. When the determined cDNA sequence was compared with an existing public DNA sequence database, it was found that the DNA sequence of one cDNA clone was a new full-length cDNA.
  • the DNA sequence contained in the new clone was bidirectionally determined by synthesizing a series of primers. Computer analysis indicated that the full-length cDNA contained in the clone was a new cDNA sequence (shown as SEQ ID NO: 1) encoding a new protein (as shown in SEQ ID NO: 2; This protein was named Rab family protein RabJ with human J domain, and its coding gene was named Rab family protein RabJ gene with human J domain.
  • SEQ ID NO: 1 is 1787 bp in length and comprises a 24 bp 5' non-coding region and a 941 bp 3' non-coding region encoding a polypeptide of 273 amino acids.
  • the unglycosylated mature molecule has a molecular weight of about 30 kD and belongs to the Rab family of molecules.
  • Example 2 Cloning of the coding sequence of human RabJ protein by RT-PCR
  • Tnzol reagent is extracted with human dendritic cells total RNA, total RNA from cells taken 5 ⁇ ⁇ 12 and 1 ⁇ ⁇ 01igo-dT - 18 were mixed and reverse transcription.
  • the reverse transcription system was 20 ⁇ l, and after the reaction was completed, 80 ⁇ l dd 3 ⁇ 40 was added for dilution.
  • the primers used for PCR amplification of RabJ were as follows: sense primer 5'-AATGGAGGCCAACATGCCG-3' (SEQ ID NO: 3), antisense primer 5'- TACTTTCTACTTGATGTT-3' (SEQ ID NO: 4), and ⁇ -actin As a positive control.
  • the PCR reaction volume was 50 ⁇ l, including the reverse transcription template 10 ⁇ l, 0.5 mM primer, 0.2 mM dNTP and B 1U rTaq DNA polymerase (Takara), and the amplification parameters were 95 ° C for 15 seconds, 57 ° C for 30 seconds, 72. After 30 seconds at °C, the PCR products were confirmed by 1.5% agarose gel electrophoresis after 28 cycles. The result of DNA sequence analysis indicated that the coding DNA sequence of the PCR product was identical to that of position 24-852 shown in SEQ ID NO: 1.
  • Example 3 Northern blot analysis of human RabJ
  • Northern blotting was performed as follows: The filter to be tested was placed in 10 ml of a pre-warmed hybridization solution at 68 ° C, pre-hybridized in a hybridization oven (Bellco) at 68 ° C for 30 minutes; the labeled cDNA probe was 95 Denature at ⁇ 100 °C for 2 to 5 minutes, add rapidly to the ice and add the hybridization solution (final concentration of cDNA probe is 2 ⁇ 10ng/ml or 1 ⁇ 2 X 10 6 cpm/ml), mix well, at 68° C hybridization for 2 hours.
  • Bellco hybridization oven
  • the filter was rinsed several times with 2xSSC, 0.05% SDS at room temperature, followed by shaking for 30 to 40 minutes, during which the lotion was changed several times. Subsequently, it was washed with 0.1 x SSC, 0.1% SDS at 50 ° C for 20 to 40 minutes. Finally, the filter was wrapped in a plastic wrap and exposed to X-ray film at -70 ° C for 24 to 48 hours.
  • the human PCR amplification product of Example 2 was used as a template, and amplification was carried out using PCR oligonucleotide primers at the 5' and 3' ends of the sequence below to obtain human RabJ DNA as an insert.
  • the 5'-end oligonucleotide primer sequence used in the PCR reaction was: 5'-GCGGATCC ATGGAGGCC AAC ATGC-3 '(SEQ ID NO: 5).
  • the 3' end primer sequence was: 5'-TCGGATCC CTACTTGATGTTTTTC -3' (SEQ ID NO: 6).
  • the obtained PCR product was purified, digested with BamH I and then recombined with the expression vector plasmid pGEX-2T (Pharmacia) according to a conventional method and transformed into competent E. coli DH5a, and the clone was picked, and the positive clone was identified by BamH I digestion.
  • the forward clones were identified by EcoR I digestion, and the products were analyzed by 0.8% agarose gel electrophoresis. After purification, it was purified and sequenced (ABI's Model 377 Sequencer, BigDye Terminator Kit, PE). It was confirmed by sequencing that the complete RabJ coding sequence has been inserted.
  • the cloning of the positive DH5a clone expressing RabJ was inoculated in 100 ml of 2xYTA medium, and cultured for 12-15 hrs at 37 °C, 300 rpm, 1 : 10 diluted in pre-warmed 2xYTA medium, and cultured for 1.5 hr, with 100 mM IPTG to O. lmM After induction at 30 ° C for 2-6 hr, 5,000 g 4 ° C centrifugation 10 mm to remove the supernatant, placed on ice with 50 ml lxPBS (0.14 M NaCl, 2.7 mM KC1, l O.
  • the RabJ protein was obtained with a molecular weight of approximately 30 kD, which was consistent with the predicted value.
  • the human RabJ recombinant protein obtained in Example 4 was used to immunize an animal to produce an antibody, and the specific method is as follows.
  • the recombinant molecules are separated by chromatography and used. Separation can also be carried out by SDS-PAGE gel electrophoresis, and the electrophoresis band is excised from the gel and emulsified with an equal volume of complete Freund's adjuvant.
  • Mice were intraperitoneally injected with 50-100 ⁇ g/0.2 ml of emulsified protein. After 14 days, mice were intraperitoneally injected with a dose of 50-100 ⁇ g/0.2 ml with the same antigen emulsified with non-complete Freund's adjuvant to boost the immunization. Enhance immunization every 14 days, at least three times.
  • the specific reactivity of the obtained antiserum was evaluated by its ability to precipitate the human RabJ gene translation product in vitro.
  • Example 6 GTP/GDP binding activity and GTPase activity analysis of human RabJ protein
  • the gel was then wrapped in a packaging film and subjected to autoradiography at -80 °C.
  • concentration of MgCl 2 was increased to 10 mM, and incubation was continued at 30 ° C.
  • Sepharose G50 column (Amersham-Phamacia) was centrifuged to remove free oc- [ 32 P]-GTP, take 1 ⁇ of eluate, spot it on polyethyleneimine cellulose filter (Sigma), perform thin layer chromatography in 1 M UC1/1 M formic acid solution, then -80 °C Autoradiography was performed.
  • the full-length plasmid DNA of Example 1 was used as a template, and amplification was carried out using PCR oligonucleotide primers at the 5' and 3' ends of the sequence below to obtain human RabJ DNA as an insert.
  • the 5' oligonucleotide primer sequence used in the PCR reaction is:
  • the 3' primer sequence is:
  • the obtained PCR product was purified, digested with BamH I-Kpn I and recombined with the eukaryotic expression vector plasmid pcDNA3.1/myc-His (-) B (Invitrogen;) by conventional methods and transformed into competent Escherichia coli DH5a. Positive clones were picked and identified, purified and sequenced (ABI's Model 377 Sequencer, B lg Dye Terminator Kit, PE). It was confirmed by sequencing that the complete RabJ coding sequence has been inserted.
  • the RabJ eukaryotic expression plasmid DNA was transfected into NIH3T3 (mouse normal fibroblast, ATCC: CRL-1658) with liposome LipofectAMINE reagent (Invitrogen) to pcDNA3.1/myc-His(-)B plasmid vector. As an irrelevant control.
  • NIH3T3 mouse normal fibroblast, ATCC: CRL-1658
  • liposome LipofectAMINE reagent Invitrogen
  • the main steps are as follows: The plasmid DNA to be transfected is mixed with the liposome LipofectAMINE in a certain ratio and allowed to react at room temperature for 45 minutes; 60-80% confluent is grown in MCF-7 cells of 6-well cell culture plate, using OPTI- After washing twice with MEM serum-free medium (Invitrogen), add the plasmid DNA-liposome mixture, incubate at 37 ° C 5% CO 2 for 6-8 hours, add an equal volume of normal medium containing 20% serum, continue Fresh medium was replaced after 6 hours of culture. Transient expression was collected 48 hours after transfection and subjected to Western blot analysis to detect transfection effects.
  • Example 8 Western blot detection
  • Cell Cellular lysate (Cell) of NIH3T3 cells transiently transfected with RabJ protein in Example 7 Signaling Inc. lyses cells. The supernatant was taken by centrifugation at 13,000 rpm x l Omin at 4 ° C, and protein quantification was performed using a BCA protein detection kit (PIERCE). The protein samples were subjected to SDS-PAGE, followed by transfer to a nitrocellulose membrane (Schleicher & Schuell) at a constant voltage of 100 V at 4 ° C, stained with Ponceau and labeled with size and orientation. Block at room temperature for 2 hours (5% skim milk powder in TBST solution), dilute the primary antibody with blocking solution, and incubate for 1 hour at room temperature.
  • PIERCE BCA protein detection kit
  • TBST (0.05% Tween 20 in TBS solution) was washed for 15 minutes, 3 times, and the secondary antibody was diluted with blocking solution and incubated for 2 hours at room temperature.
  • the TBST was washed for 15 minutes, 3 times, washed with TBS (10 mM Tns-HCl, pH 8.0, 150 mM NaCl) for 15 minutes, then added with a chemiluminescent substrate (Pierce) for 1 mm, and rapidly sealed and auto-developed.
  • the primary antibody used for Western blot detection was the anti-RabJ antibody obtained in Example 5.
  • the secondary antibody was HRP-labeled anti-rabbit IgG (Cell Signaling).
  • the expression product of RabJ has a molecular weight of 30 KD (Fig. 3).
  • Example 9 RNA interference analysis of human RabJ
  • RNAi vector pSuppressorNeo sense strand 5'- U CAU CUC CAU GGG CAA CGC -3' (SEQ ID NO: 9) and the antisense strand 5'-GCG UUG CCC AUG GAG AUG A (SEQ ID NO: 10).
  • a 21-nt long randomized control oligonucleotide was also inserted into this vector as a control: sense strand 5'-UCA GUC ACG UUA AUG GUC GUU (SEQ ID NO: 1 1) and antisense strand 5'-AAC GAC CAU UAA CGU GAC UGA (SEQ ID NO: 12).
  • ATCC: CCL-2) and MCF-7 human breast cancer cells, ATCC: HTB-22 are used to interfere with the expression of RabJ protein in cells.
  • the main steps are the same as in Example 7. 48 hours after transfection, cells were harvested for RT-PCR (main steps as in Example 2) and Western blot analysis (main steps as in Example 8) for RabJ protein expression.
  • the [ 3 H]-thymidine incorporation method was employed.
  • NIH3T3 cells overexpressing RabJ in Example He, HeLa or MCF-7 cells inhibiting RabJ expression in Example 9 were plated at 5 ⁇ 10 4 /well in 24-well culture plates (Falcon), three cells per cell. hole. After 6 h of culture, the culture was continued for 24 to 48 h in serum-free medium, and 0.5 ⁇ L was added to each well for the last 4 h.
  • ⁇ (1 Ci 37 GBq) of [ 3 H]-thymidine (Amersham-Phamacia). Then, it was washed three times with PBS, and the cells were dissolved in PBS containing 1% Triton X-100, collected with a glass fiber filter, and radioactivity was measured with a liquid scintillation meter.
  • a clone formation assay was used. In order to examine the ability of cells to grow independently of growth, the NIH3T3 cells stably overexpressing RabJ in Example 7, and the HeLa or MCF-7 cells (5 x 10 4 ) inhibiting RabJ expression in Example 9 were suspended in 0.5% soft agar. Place in a 6-well plate containing 1% soft agar. After 3 weeks of culture, clones larger than 50 cells were recorded as positive by light microscopy.
  • the NIH3T3 cells stably expressing RabJ in Example 7, and the HeLa cells (1 x 10 6 ) inhibiting RabJ expression in Example 9 were subcutaneously injected into the right lower abdomen of Balb/C nude mice, and then the growth rate of the tumor was observed or The incidence of tumors (number of mice in which tumors appeared / number of nude mice injected with cells). Tumor size was measured with a vernier caliper (unit: mm) and the result was length X width X width (tumor volume; unit: mm 3 ). Observe for six weeks.
  • NIH3T3 cells expressing full-length RabJ could form tumor nodules (100%) in vivo, whereas wild-type and control vector-transfected NIH3T3 cells could not form tumors (0% Figure 9), while RabJ protein expression was down-regulated.
  • Post-HeLa cells showed a decrease in tumorigenicity in vivo (Fig. 10A), and the rate of tumor growth that had formed was also reduced (Fig. 10B). Discussion
  • Rab Ras-like protein in rat brain
  • Ras superfamily The basic biochemical feature is that it can bind GTP/GDP and hydrolyze GTP.
  • Rab3a is mainly distributed in neural tissue and secretory cell lines, and is mainly involved in the regulation of neurotransmitter secretion.
  • Rab3a knockout mice develop normally, but show short- and long-term synaptic plasticity defects in the mossy fiber pathway, and abnormal circadian activity cycles.
  • Rab5 is a widely distributed Rab protein that is primarily localized in early endocytosis and is involved in the regulation of endocytic pathways, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF) receptor EGFR, and PDGFR endocytosis, thereby participating in signals. Regulation of conduction.
  • EGF epidermal growth factor
  • PDGF platelet-derived growth factor
  • GnscelU syndrome is a disease caused by abnormal pigmentation and pigmentation and T lymphocyte killing dysfunction. It is found that the mutation of Rab27a is the occurrence of the disease. Genetic cause.
  • Abnormalities in the Rab7 protein can cause abnormalities in the metabolism of lipoproteins, causing hyperlipidemia and vascular diseases; some intracellular bacteria, such as Mycobacterium tuberculosis, can inhibit the function of Rab7 to infect the host and cause disease.
  • Abnormalities in Rab regulatory proteins are also the cause of certain diseases, such as choroidal disorders, X-linked neurodegenerative disorders; abnormalities in post-translational modification of Rab proteins can cause Hermansky-Pudlak syndrome.
  • Rab proteins may be involved in tumorigenesis.
  • abnormal expression of Rab protein is found in certain tumor cells or tumor types.
  • Rab25 is highly expressed in prostate cancer, and its expression level is closely related to the differentiation and clinical stage of prostate cancer.
  • Rab38 expression is also significantly increased in melanoma cell lines;
  • Rab3 is also highly expressed in pituitary adenocarcinoma.
  • Rab2 expression was significantly increased in peripheral blood mononuclear cells of hematopoietic tumors and solid tumor patients; Rab2 expression was also abnormal in mouse adrenal and mouse lung cancers.
  • Second, a deletion mutation in the Rab gene was found in the tumor.
  • a deletion of the chromosome 22ql l.2 region was found in malignant rhabdomyosarcoma, which contains the coding region of Rab36.
  • abnormalities in Rab regulatory proteins have also been found in tumors.
  • the expression of the Rab protein regulatory protein RabGDI is significantly increased.
  • the expression of Rab GTPase-activating protein, PRC17 which regulates GTP hydrolysis of Rab5 protein, can affect tumor growth characteristics.
  • the RabJ protein of the present invention is highly expressed in various tumor cells, and the normal fibroblast NIH3T3 is transformed after high expression of RabJ, which is expressed as a colony formed on a semi-solid agar plate, and RabJ-transformed NIH3T3 cells can be used in nude mice. Formation of fibroblastic sarcoma. RabJ can promote cell proliferation. Blocking the expression of RabJ using RNA interference technology can inhibit the proliferation of tumor cells, resulting in decreased tumorigenicity and decreased tumor growth rate in vivo. The above experimental results of the present invention suggest that RabJ is involved in cell proliferation and cell cycle progression, and thus RabJ can be used as an effective tumor therapeutic target.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne la petite protéine G humaine de type oncogène RabJ (protéine Rab avec un domaine J), ainsi que ses utilisations et sa séquence codante. La molécule RabJ est une petite protéine G présentant une activité GTPase qui est associée au contrôle de la prolifération et de la différenciation cellulaire et qui possède une action de type oncogène.
PCT/CN2007/070623 2007-09-04 2007-09-04 NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ WO2009030084A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070623 WO2009030084A1 (fr) 2007-09-04 2007-09-04 NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070623 WO2009030084A1 (fr) 2007-09-04 2007-09-04 NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ

Publications (1)

Publication Number Publication Date
WO2009030084A1 true WO2009030084A1 (fr) 2009-03-12

Family

ID=40428435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070623 WO2009030084A1 (fr) 2007-09-04 2007-09-04 NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ

Country Status (1)

Country Link
WO (1) WO2009030084A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408724A (zh) * 2001-09-21 2003-04-09 第二军医大学免疫学研究所 新的睾丸功能相关蛋白及其用途
CN1948483A (zh) * 2005-10-12 2007-04-18 中国人民解放军第二军医大学 抑制人RabJ基因表达的siRNA及其应用
CN1948482A (zh) * 2005-10-12 2007-04-18 中国人民解放军第二军医大学 抑制人RabJ基因表达的反义寡核苷酸序列及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408724A (zh) * 2001-09-21 2003-04-09 第二军医大学免疫学研究所 新的睾丸功能相关蛋白及其用途
CN1948483A (zh) * 2005-10-12 2007-04-18 中国人民解放军第二军医大学 抑制人RabJ基因表达的siRNA及其应用
CN1948482A (zh) * 2005-10-12 2007-04-18 中国人民解放军第二军医大学 抑制人RabJ基因表达的反义寡核苷酸序列及其应用

Similar Documents

Publication Publication Date Title
US8030015B2 (en) Tumor-inhibiting protein and the use thereof
WO2009030084A1 (fr) NOUVELLES FONCTIONS ET UTILISATIONS DE LA PETITE PROTÉINE G HUMAINE DE TYPE ONCOGÈNE RabJ
WO2001038522A1 (fr) Nouveau polypeptide, histone humaine h2a.21, et polynucleotide codant pour ce polypeptide
US7250488B1 (en) Transcriptional activation inhibitory protein
WO2009030093A1 (fr) Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine
US20030148331A1 (en) Novel human hepatoma associated protein and the polynucleotide encoding said polypeptide
WO2004052927A1 (fr) Gene associe a la calvitie et polypeptide code par ce gene, et utilisations correspondantes
WO2001032699A1 (fr) Nouveau polypeptide, nouvelle udp glucose-glycoproteine glucosyltransferase (« biohugtr »), et polynucleotide codant pour ce polypeptide
WO2001029228A1 (fr) Nouveau polypeptide, caseine kinase humaine 48, et polynucleotide codant pour ce polypeptide
WO2001038545A1 (fr) Nouveau polypeptide, acetyle galactosyle transferase 45 humain et polynucleotide codant ce polypeptide
WO2001030818A1 (fr) Nouveau polypeptide, proteine de liaison 33 a l'arn, et polynucleotide codant pour ce polypeptide
WO2009030086A1 (fr) Fonctions et utilisations d'un inhibiteur de croissance dérivé des cellules stromales de la moelle osseuse humaine
WO2009030087A1 (fr) Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine
WO2009030088A1 (fr) Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline
WO2001030837A1 (fr) Nouveau polypeptide, galectine 15, et polynucleotide codant pour ce polypeptide
WO2001031023A1 (fr) Nouveau polypeptide, proteine precurseur humaine 25 de la nucleoproteine ii, et polynucleotide codant pour ce polypeptide
WO2003057883A1 (fr) Facteur 5 de croissance derive de l'hepatome humain, sa sequence codante, procede pour le produire et ses utilisations
WO2001030838A1 (fr) Nouveau polypeptide, proteine g 17, et polynucleotide codant pour ce polypeptide
WO2001030821A1 (fr) Nouveau polypeptide, arn cyclase humaine 41, et polynucleotide codant pour ce polypeptide
WO2002022676A1 (fr) Proteine garante de longevite, sa sequence de codage et ses utilisations
WO2001030840A1 (fr) Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001030825A1 (fr) Nouveau polypeptide, facteur humain d'epissage 25, et polynucleotide codant pour ce polypeptide
WO2001030832A1 (fr) Nouveau polypeptide, proteine a doigt de zinc hkznf-23, et un polynucleotide codant pour ce polypeptide
WO2001031024A1 (fr) Nouveau polypeptide, threonine synthetase 71, et polynucleotide codant pour ce polypeptide
WO2001029076A1 (fr) Nouveau polypeptide, une proteine-22 humaine p24, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801032

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801032

Country of ref document: EP

Kind code of ref document: A1